Cambrex acquired Avista in 2019, following previous acquisition of Solid Form Solutions Ltd, a world leading contract research organisation (CRO) providing the pharmaceutical industry with chemical development services.
Fresh insights into the biological causes of stroke could pave the way for new therapies, following a study carried out by researchers, including experts from the University of Edinburgh’s Usher Institute.
New software, created by scientists at Imperial College London and the University of Edinburgh, has been able to identify and measure the severity of small vessel disease, one of the commonest causes of stroke and dementia.
CALCIVIS, a medical devices company focused on revolutionising the management of tooth decay and enabling preventive dentistry, announces it has closed a £3.15 million equity funding round from existing investors Archangel Investors, Julz and the Scottish...
Midlothian-based industrial biotechnology company Ingenza is working with the National Physical Laboratory and the University of Plymouth to develop a design and manufacturing platform for the production of a new family of antibiotics.
Physiologically relevant human models of chronic pain are essential to developing new therapeutics and overcome poor translation between animal studies and the clinical setting. Learn more in an upcoming webinar on stem cell-based pain and CNS drug discov...
Scientists at the University of Dundee, working with Sasol UK and Ingenza Ltd, have discovered that E. coli bacteria could hold the key to an efficient method of capturing and storing or recycling carbon dioxide.
Experts are to tackle one of the biggest health challenges facing society - the ability of common infections to resist drug treatment - in a new facility being created at the University's King's Buildings campus.
Synpromics Ltd is pleased to announce a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system (CNS), to develop a gene therapy for Parkinson’s disease.
Synpromics Ltd, the leader in gene control, announces a collaboration with UCL Great Ormond Street Institute of Child Health, to develop novel gene therapies for pathologies affecting the haematopoietic system.
Ingenza, a leader in the application of industrial biotechnology and synthetic biology, is pleased to announce that it has become a stakeholder in Amprologix, a spin-out company from the University of Plymouth.
Cutting edge research and development programmes at the "Incubated Worlds" poultry facility will be lead by the Centre for Tropical Livestock Genetics and Health - a strategic alliance of The University of Edinburgh (through The Roslin Institute), Scotlan...
The workshop, hosted by the Department of Animal Husbandry and Veterinary Services, brought together stakeholders from across government departments, fostering a One Health perspective on rabies control
1851 Royal Commission Fellowship has funded innovative doctoral research with commercial potential for Dr Stephen McColm to develop an enhanced DNA assembly approach based on the company’s proprietary inABLE® technology.
Bill Gates and Government Minister Penny Mordaunt are to showcase how communities worldwide are being helped by innovative agricultural research during a visit to the University of Edinburgh’s Easter Bush Campus.
John Mackenzie, CEO of Roslin Innovation Centre, gives an insight into the role of the new business gateway during Edinburgh's Life Sciences focus week, part of Visit Scotland's Legends campaign - Scotland Where #IdeasBecomeLegend.